#USA #AI Technology #Aignostics #Berlin and New York #Atlas HE-TME

Aignostics Unveils Atlas HE-TME: Transforming Cancer Research with AI

Aignostics, a prominent player in artificial intelligence for medical applications, has just launched its groundbreaking application, Atlas HE-TME, designed for tumor microenvironment (TME) analysis. This innovative tool is set to revolutionize cancer research by allowing experts to extract intricate details from histological images without the need for complex stains or extensive processing.

What is Atlas HE-TME?

Atlas HE-TME is designed to streamline the analysis of whole-slide images, providing insights in mere hours. This tool enables researchers to characterize immune cell populations, spatial relationships, and tissue architecture across various types of cancers. The app is built on Aignostics' leading foundation model, co-developed with renowned institutes like the Mayo Clinic and Charité Berlin, ensuring high accuracy and reliability in data analytics.

Key Features and Benefits

One of the standout features of Atlas HE-TME is its capability to deliver over 5,000 quantitative metrics per image, assessing seven different tissue types and nine cell classes. This allows for detailed quality control and comprehensive research insights. Additionally, the self-service application is designed for easy integration with major image management systems, making it a versatile choice for researchers and biopharma companies alike.

Frederick Klauschen, MD, co-founder of Aignostics, expressed enthusiasm about the application's performance across multiple cancer types, emphasizing its accuracy and robustness. This kind of quality is essential as the understanding of the tumor microenvironment is crucial for developing effective cancer therapies.

Addressing Critical Bottlenecks in Cancer Research

The advent of Atlas HE-TME could alleviate some of the significant hurdles in cancer research. Traditional methods of analyzing tumor microenvironments are often slow, expensive, and may lack the scalability needed for larger studies. With Atlas HE-TME, Aignostics aims to change the paradigm by providing rapid, high-quality analyses that can lead to deeper insights and faster discoveries.

Viktor Matyas, co-founder and CEO of Aignostics, noted that early access collaborations with major biopharma organizations have confirmed the tool's effectiveness at delivering valuable insights from HE images. These results are vital for researchers looking to maximize every detail captured in their analysis.

Diverse Applications in Cancer Research

The applications of Atlas HE-TME are vast. Researchers can utilize it for a variety of purposes, such as identifying and characterizing tumors with immune infiltration or integrating HE data with spatial transcriptomics to refine cell niche analyses. Initially available for key cancer types including breast, bladder, colorectal, liver, and lung cancers, Aignostics plans to expand access to academic institutions and introduce more cancer types and analytical capabilities in the coming months.

Aignostics: A Leader in AI-Powered Medical Insights

Founded in 2020 as a spin-off from Charité Berlin, Aignostics is at the forefront of using AI to turn complex pathology data into actionable insights for precision medicine. The company combines unparalleled access to multi-modal clinical data with robust AI technologies, developing products that support the entirety of drug development—from discovery and translational research to clinical trials and companion diagnostics.

With a growing team of over 120 employees based in Berlin and New York, Aignostics is making strides in improving cancer research methodologies and outcomes. As interest in their new application grows, the company invites organizations curious about a free trial to explore their offerings on their official website.

For more details, visit Aignostics and follow them on LinkedIn for updates and announcements.